MAPT
Microtubule-associated protein tau
As of the edition of 20 October 2026, MAPT (microtubule-associated protein tau, UniProt P10636) has 14 drugs tested at it and 16 companies on the list, 5 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P10636
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 311
- Disease areas
- Nervous system; Mental health; Eye; Nutrition and metabolism; Injuries; Heart and blood vessels; Hormones; Immune system
- Registered trials of its drugs
- 117
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 6 |
| Stopped | 5 |
| Status not established | 1 |
| Total | 14 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Flortaucipir | Marketed | Phase 4 | Ends 2032 |
| Florquinitau | Marketed | Phase 3 | Ends 2035 |
| PI-2620 | Active | Phase 3 | none listed |
| Hydromethylthionine | Stopped | Phase 3 | none listed |
| Tilavonemab | Stopped | Phase 2 | none listed |
| Gosuranemab | Stopped | Phase 2 | none listed |
| Bepranemab | Active | Phase 2 | none listed |
| BMS-986446 | Active | Phase 2 | none listed |
| Posdinemab | Stopped | Phase 2 | none listed |
| NIO752 | Active | Phase 3 | none listed |
| Semorinemab | Stopped | Phase 2 | none listed |
| Zagotenemab | Status not established | Phase 2 | none listed |
12 of 14 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 5 |
| Route B | 2 |
| Engaged | 9 |
| Total on the list | 16 |
| Company | Route |
|---|---|
| Eli Lilly | Route B |
| Biogen | Route A |
| Avid Radiopharmaceuticals | Route B |
The other 13 companies at MAPT
In the product16 companies in all; 13 are not named here, and no score is.
See the 16 companies at MAPT, ranked, with the facts behind eachRequest access. Nothing is shown until you do.